Evidence map›Paper›PMID 36581345›Full record

ArticleCancer genomics & proteomics

Small RNA Sequencing Identifies a Six-MicroRNA Signature Enabling Classification of Brain Metastases According to their Origin.

Ivana Roskova, Marek Vecera, Lenka Radova, Karolina Trachtova, Frantisek Siegl, Marketa Hermanova, Michal Hendrych, Leos Kren, Vaclav Vybihal, Hana Valekova and 7 more

Open access · diamondAbstract read
In one paragraph

Article in Cancer genomics & proteomics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 6 institutions in 1 country.

Ivana RoskovaDepartment of Neurosurgery, University Hospital Brno, Brno, Czech Republic.
Marek VeceraCentral European Institute of Technology, Masaryk University, Brno, Czech Republic.
Lenka RadovaCentral European Institute of Technology, Masaryk University, Brno, Czech Republic.
Karolina TrachtovaCentral European Institute of Technology, Masaryk University, Brno, Czech Republic.
Frantisek SieglCentral European Institute of Technology, Masaryk University, Brno, Czech Republic.
Marketa HermanovaFaculty of Medicine, Masaryk University, Brno, Czech Republic.
Michal HendrychFaculty of Medicine, Masaryk University, Brno, Czech Republic.
Leos KrenDepartment of Pathology, University Hospital Brno, Brno, Czech Republic.
Vaclav VybihalDepartment of Neurosurgery, University Hospital Brno, Brno, Czech Republic.
Hana ValekovaFaculty of Medicine, Masaryk University, Brno, Czech Republic.
Petra KasparovaThe Fingerland Department of Pathology, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic.
Ivana KolouskovaFaculty of Medicine, Masaryk University, Brno, Czech Republic.
Tomas KazdaFaculty of Medicine, Masaryk University, Brno, Czech Republic.
Ondrej SlabyCentral European Institute of Technology, Masaryk University, Brno, Czech Republic.
Radim JancalekFaculty of Medicine, Masaryk University, Brno, Czech Republic.
Jiri SanaCentral European Institute of Technology, Masaryk University, Brno, Czech Republic; sana.jiri@gmail.com.
Martin SmrckaDepartment of Neurosurgery, University Hospital Brno, Brno, Czech Republic; smrcka.martin@fnbrno.cz.
Central European Institute of Technology – Masaryk University · CZMasaryk University · CZUniversity Hospital Brno · CZCentral European Institute of Technology · CZSt. Anne's University Hospital Brno · CZUniversity Hospital Hradec Králové · CZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimBrain metastases (BMs) are the most frequent intracranial tumors in adults and one of the greatest challenges for modern oncology. Most are derived from lung, breast, renal cell, and colorectal carcinomas and melanomas. Up to 14% of patients are diagnosed with BMs of unknown primary, which are commonly characterized by an early and aggressive metastatic spread. It is important to discover novel biomarkers for early identification of BM origin, allowing better management of patients with this disease. Our study focused on microRNAs (miRNAs), which are very stable in frozen native and FFPE tissues and have been shown to be sensitive and specific diagnostic biomarkers of cancer. We aimed to identify miRNAs with significantly different expression in the five most frequent groups of BMs and develop a diagnostic classifier capable of sensitive and specific classification of BMs. MATERIALS AND

methodsTotal RNA enriched for miRNAs was isolated using the mirVana miRNA Isolation Kit from 71 fresh-frozen histopathologically confirmed BM tissues originating in 5 cancer types. Sequencing libraries were prepared using the QIAseq miRNA Library Kit and sequenced on the NextSeq 500 platform. MiRNA expression was further validated by RT-qPCR.

resultsDifferential analysis identified 373 miRNAs with significantly different expression between 5 BM groups (p<0.001). A classifier model was developed based on the expression of 6 miRNAs (hsa-miR-141-3p, hsa-miR-141-5p, hsa-miR-146a-5p, hsa-miR-194-5p, hsa-miR-200b-3p and hsa-miR-365b-5p) with the ability to correctly classify 91.5% of samples. Subsequent validation confirmed both significantly different expression of selected miRNAs in 5 BM groups as well as their diagnostic potential.

conclusionTo date, our study is the first to analyze miRNA expression in various types of BMs using small RNA sequencing to develop a diagnostic classifier and, thus, to help stratify BMs of unknown primary. The presented results confirm the importance of studying the dysregulated expression of miRNAs in BMs and the diagnostic potential of the validated 6-miRNA signature.

Indexed as

Brain NeoplasmsMelanomaMicroRNAsNeoplasms, Unknown PrimaryAdultBiomarkersHumansBiomarkersMicroRNAsBrain metastasesclassifierdiagnosismicroRNAsmall RNA sequencing

Identifiers

PMID36581345
PMCPMC9806667
OpenAlexW4313424185

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.